Company News for Sep 21, 2020
Companies in the news are: RHHBY, PIC, IMMP, JAX
Zacks · 6d ago
VALE, AGEN among premarket gainers
Cassava Sciences (SAVA) +27% on insider buying.Immutep (IMMP) +21% on encouraging results from mid-stage TACTI-002 study.ClearOne (CLRO) +13% on insider buying.Sonoma Pharmaceuticals (SNOA) +12% on receiving approval by Health Canada for their patented and trademarked Nanocyn®
Seekingalpha · 09/18 12:13
The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 17)
Benzinga · 09/18 11:30
Immutep Last Night Announced Improving Results from INSIGHT-004 Trial
Immutep Limited (NASDAQ: IMMP) is pleased to report further interim data from its ongoing INSIGHT-004 Phase I clinical trial.
Benzinga · 09/18 09:46
Immutep Announced Last Night Improving Results from Stage I of Phase II TACTI-002 Study
Immutep Limited (NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study. The data was presented in two poster presentations at the ESMO Virtual Congress 2020 on 17 September 2020 and relates to the cut-off date of 21 August 2020.
Benzinga · 09/18 09:45
Immutep presents improving results from INSIGHT-004 trial
Immutep (IMMP) reports further interim data from its ongoing INSIGHT-004 Phase I clinical trial. The data were presented at the ESMO Virtual Congress 2020 and relates to the cut-off date of
Seekingalpha · 09/18 06:14
Immutep reports encouraging results from mid-stage TACTI-002 study
Immutep (IMMP) announces new interim data from its ongoing Phase II TACTI-002 study. The data was presented at the ESMO Virtual Congress 2020 and relates to the cut-off date of
Seekingalpha · 09/18 05:55
Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study
* Three complete responses (complete disappearance of all lesions) reported: two in 2nd line head and neck squamous cell carcinoma (HNSCC) and one in 1st line non-small cell lung cancer (NSCLC) * Five responses in patients (both indications) with negative (< 1%) or moderate PD-L1 expression where
GlobeNewswire · 09/18 01:23
Immutep Reports Improving Results from INSIGHT-004 Trial
* 41.7% of patients showed a Partial Response to the combination therapy of eftilagimod alpha and avelumab (previously 33%) * Encouraging early anti-tumour activity signals in a variety of cancer indications not typically sensitive to immune checkpoint inhibitor (ICI) therapy * Combination of eftilagimod
GlobeNewswire · 09/17 23:53
The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16)
Benzinga · 09/17 11:59
The Week Ahead In Biotech: Decision Day For Bausch Health, IPO Flow Resumes, Oncology Conference
Biotech stocks continued to remain under pressure in the week ended Sept. 11, swayed by the volatility that was evident in the broader market.
Benzinga · 09/13 13:49
Immutep, Monash University Receive A$671,427 In Grant Funding For LAG-3 Project
Immutep and Monash University Receive Grant Funding for LAG-3 Project SYDNEY, Australia, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) is pleased to announce that the Australian
Benzinga · 08/31 12:14
How Should Investors Feel About Immutep's (ASX:IMM) CEO Remuneration?
Marc Voigt has been the CEO of Immutep Limited (ASX:IMM) since 2014, and this article will examine the executive's...
Simply Wall St. · 08/28 06:15
New Data From Immuteps efti to be Presented at ESMO
GlobeNewswire · 08/26 13:00
CRM, HPE among premarket gainers
Tyme Technologies (TYME) +29% as oncology research reveals potential new oral therapy TYME-19 in the fight against COVID-19.SCWorx (WORX) +32%.Immunic (IMUX) +20% as Piper goes bargain shopping.Heat Biologics (HTBX) +19%
Seekingalpha · 08/26 12:21
Immutep Completes Recruitment for Stage 1 of Part B in TACTI-002 Study
GlobeNewswire · 08/18 12:00
Immutep Issues Newsletter Update to Shareholders
LAG-3 Therapeutic Landscape Overview Formatted version of this update available on the Company’s website www.immutep.comSYDNEY, Australia, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy
GlobeNewswire · 08/17 13:00
GOLD, OSTK among premarket gainers
CureVac (CVAC) +47% on making reasonable profit on COVID-19 vaccine.LMP Automotive (LMPX) +42% on Q2 results.Microbot Medical (MBOT) +38% on successful study of surgical robot.Sonoma Pharmaceuticals (SNOA) +13% on FQ1 results.CooTek (CTK) +19%.Mustang Bio
Seekingalpha · 08/17 12:35
Immutep Granted U.S. Patent For Eftilagimod Alpha In Chemo-Immunotherapy Combination
Benzinga · 08/11 12:16
Immutep shares are trading higher after the company announced it has been granted a US Patent for Eftilagimod Alpha in Chemo-immunotherapy combination.
Benzinga · 08/11 11:00
Webull provides a variety of real-time IMMP stock news. You can receive the latest news about Immutep through multiple platforms. This information may help you make smarter investment decisions.
Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.More